1000104906.jpg

Am a 2nd yr mbbs student indian

Reading File

Finding Sources

Here are complete model answers for your entire Pathology-A paper:

MBBS 2nd Phase - Pathology A (10123-A) - Complete Answers

PART I

Q.2 - Case: 45-year-old male, WBC = 2,00,000 cells/mm³, massive splenomegaly, weight loss, night sweats

a. Diagnosis (1 mark)

Chronic Myeloid Leukemia (CML)

The classic triad supporting this:

Massive splenomegaly (hallmark)
Very high WBC (leukocytosis >1,00,000/mm³)
Constitutional symptoms: weight loss, night sweats, anorexia, fatigue

b. Relevant Investigations to Confirm Diagnosis (5 marks)

1. Peripheral Blood Smear

Marked leukocytosis with the full myeloid series: myeloblasts, promyelocytes, myelocytes, metamyelocytes, bands, mature neutrophils
"Myelocyte bulge" - myelocytes predominate
Basophilia and eosinophilia
Thrombocytosis may be present
Low LAP (Leukocyte Alkaline Phosphatase) score - KEY differentiator from leukemoid reaction

2. Bone Marrow Biopsy / Aspirate

Hypercellular marrow with myeloid hyperplasia
Myeloid:Erythroid ratio increased (10:1 or more)
Megakaryocytes increased (dwarf megakaryocytes)
Blasts <10% in chronic phase

3. Cytogenetics - Karyotyping

Demonstrates t(9;22)(q34;q11) - the Philadelphia chromosome
Standard: Conventional G-banding karyotype

4. Fluorescence In Situ Hybridization (FISH)

Detects BCR-ABL1 fusion gene (even when Ph chromosome not visible)
More sensitive than karyotyping

5. RT-PCR (Reverse Transcriptase-PCR)

Detects BCR-ABL1 mRNA transcript
Most sensitive (1 in 10⁵ cells) - used for minimal residual disease (MRD) monitoring
Distinguishes p210 (typical CML) vs p190 (ALL type) transcript

6. Complete Blood Count

WBC markedly elevated (typically 1,00,000 - 5,00,000/mm³)
Differential shows all myeloid stages
Hemoglobin may be low
Platelets variable

7. LFT/USG Abdomen - Hepatosplenomegaly confirmation; Serum uric acid raised (cell turnover)

c. Chromosomal Abnormality (2 marks)

Philadelphia Chromosome (Ph chromosome)

Translocation: t(9;22)(q34;q11)
A piece of chromosome 9 (containing ABL1 proto-oncogene at q34) translocates to chromosome 22 (containing BCR gene at q11)
This creates the BCR-ABL1 fusion gene on the shortened chromosome 22 (Philadelphia chromosome)
The BCR-ABL1 fusion protein has constitutively active tyrosine kinase activity - it continuously phosphorylates downstream signaling molecules (RAS, PI3K, STAT5), promoting:
- Uncontrolled proliferation
- Inhibition of apoptosis
- Defective adhesion to bone marrow stroma
This is the target for imatinib (Gleevec) - a tyrosine kinase inhibitor (TKI)
Present in >95% of CML cases
Residual chromosome 22 = Philadelphia chromosome; chromosome 9 gets the BCR sequences

d. Phases of CML (2 marks)

Phase	Features
Chronic Phase	Most patients diagnosed here. WBC raised, <10% blasts in blood/marrow. Responds well to TKIs. Duration: 3-5 years if untreated
Accelerated Phase	10-19% blasts; basophils >20%; thrombocytopenia unrelated to treatment; cytogenetic clonal evolution (e.g., trisomy 8, isochromosome 17q). Duration: 6-18 months
Blast Crisis (Blast Phase)	≥20% blasts (myeloid 70%, lymphoid 30%). Resembles acute leukemia. Fatal if untreated. Median survival 3-6 months

Q.3 - Describe Briefly (5 marks each)

a. Pathogenesis of Granuloma Formation

A granuloma is a focal aggregate of activated macrophages (epithelioid cells), often with multinucleated giant cells, surrounded by a collar of lymphocytes.

Steps in formation:

Stimulus: An agent that cannot be destroyed by routine phagocytosis - e.g., Mycobacterium tuberculosis (waxy cell wall), fungi, foreign material, beryllium
Initial macrophage activation: The agent is engulfed by macrophages. If not killed, macrophages present antigens to CD4+ T helper cells (Th1 subtype)
T-cell activation & IFN-γ secretion: Th1 cells secrete IFN-γ - the most important activator of macrophages. Also IL-2 (T-cell proliferation), TNF-α
Macrophage transformation: Under IFN-γ stimulation, macrophages transform into epithelioid cells (elongated, pale eosinophilic cytoplasm, vesicular nuclei) - increased secretory activity but reduced phagocytic ability
Giant cell formation: Epithelioid cells fuse → Langhans giant cells (nuclei arranged in horseshoe/peripheral pattern - TB) or Foreign body giant cells (nuclei scattered centrally)
Central necrosis (caseous necrosis in TB) - due to tissue hypoxia and toxic macrophage products
Fibrosis: Over time, fibroblasts encircle the granuloma → fibrous cuff → calcification (Ghon focus)

Types:

Caseating (TB, histoplasmosis) - with central cheese-like necrosis
Non-caseating (sarcoidosis, Crohn's, berylliosis, leprosy - tuberculoid type)

b. Tumor Suppressor Genes & Role of p53 in Tumorigenesis

Tumor suppressor genes (anti-oncogenes) - Normally restrain cell growth. Loss of both alleles (two-hit hypothesis - Knudson) leads to cancer.

Major TSGs:

p53 (chromosome 17p13) - "Guardian of the genome"
Rb (retinoblastoma protein) - chromosome 13q14
BRCA1/2 - breast/ovarian cancer
APC - colorectal cancer
PTEN - multiple cancers
VHL - renal cell carcinoma
NF1, NF2 - neurofibromatosis
WT1 - Wilms tumor

Role of p53 in Tumorigenesis:

Under normal conditions, p53 is expressed at low levels (rapidly degraded by MDM2).

When DNA is damaged:

Kinases (ATM, ATR, Chk1, Chk2) phosphorylate p53 → p53 stabilized and activated
p53 acts as a transcription factor → activates target genes:

Function	Mechanism
Cell cycle arrest	Activates p21 → inhibits CDK4/Cyclin D → Rb stays hypophosphorylated → E2F blocked → G1 arrest
DNA repair	Upregulates GADD45 (DNA repair protein)
Apoptosis (if irreparable)	Upregulates BAX, PUMA, NOXA (pro-apoptotic) → cytochrome c release → caspase cascade
Senescence	Prevents proliferation of damaged cells

In cancer:

p53 is mutated in >50% of all human cancers (most common mutation)
Loss → cells with damaged DNA bypass arrest → accumulate mutations → malignant transformation
Li-Fraumeni syndrome = germline p53 mutation → multiple early cancers
MDM2 amplification (inactivates p53) seen in sarcomas

c. Differences Between Benign and Malignant Tumors

Feature	Benign	Malignant
Differentiation	Well-differentiated (resembles parent tissue)	Poorly/un-differentiated (anaplastic)
Rate of growth	Slow, progressive	Rapid, unpredictable
Mode of growth	Expansive, pushing margins	Infiltrative, invasive margins
Capsule	Usually encapsulated	No capsule (except thyroid Ca, RCC)
Metastasis	Absent	Present (hallmark of malignancy)
Recurrence	Rare after excision	Common
Necrosis/ulceration	Absent	Frequent
Mitoses	Rare, normal (typical)	Frequent, atypical
Nuclear features	Normal N:C ratio, regular	Hyperchromasia, pleomorphism, prominent nucleoli, ↑ N:C ratio
Angiogenesis	Not prominent	Tumor angiogenesis (VEGF)
Effect on host	Local pressure only	Cachexia, paraneoplastic syndromes, death
Examples	Lipoma, leiomyoma, adenoma	Liposarcoma, leiomyosarcoma, adenocarcinoma

d. Clinical Features of Systemic Lupus Erythematosus (SLE)

SLE is a chronic autoimmune disease with multisystem involvement. Mnemonic: SOAP BRAIN MD

System	Features
Skin	Butterfly (malar) rash (fixed erythema over cheeks/nose), discoid rash, photosensitivity, oral ulcers (painless)
Joints	Arthritis/arthralgia (non-erosive, migratory) - most common symptom (>90%); Jaccoud arthropathy
Kidney	Lupus nephritis (WHO Class I-VI) - most serious; proteinuria, hematuria, nephrotic syndrome, renal failure
Hematology	Hemolytic anemia, leukopenia (<4000), lymphopenia (<1000), thrombocytopenia (<100,000)
CNS	Seizures, psychosis, cerebritis, peripheral neuropathy, stroke
Cardiovascular	Pericarditis (most common cardiac), Libman-Sacks endocarditis (non-infective), myocarditis
Pulmonary	Pleuritis, pleural effusion, lupus pneumonitis, pulmonary HTN
Constitutional	Fever, fatigue, weight loss, lymphadenopathy
Raynaud's	Vasospasm of fingers

Key Autoantibodies:

ANA - highly sensitive (95%); screening test
Anti-dsDNA - highly specific (70%); correlates with disease activity
Anti-Sm - most specific (25-30%)
Anti-phospholipid - thrombosis, recurrent abortions

e. Difference Between Necrosis and Apoptosis

Feature	Necrosis	Apoptosis
Cause	Pathological (ischemia, toxins, infection)	Physiological or pathological
Mechanism	Uncontrolled, accidental	Programmed, regulated (gene-directed)
Cell size	Swelling → cell rupture	Shrinkage (condensation)
Nucleus	Karyolysis, karyorrhexis, pyknosis	Chromatin condensation, margination; nuclear fragmentation
Membrane	Disrupted early	Intact until late; blebbing
Cellular contents	Released (leakage)	Packaged into apoptotic bodies
Inflammation	YES - triggers acute inflammation	NO - apoptotic bodies phagocytosed quietly
Extent	Groups of cells affected	Individual cells
Reversibility	Irreversible	Can be reversible early
DNA	Random degradation	Internucleosomal (ladder pattern on gel)
Examples	MI, gangrene, caseous necrosis	Embryogenesis, thymic deletion, cancer therapy
Biochemical marker	LDH, CK (enzymes released)	Caspase activation; Annexin V binding

f. Clinical and Cytogenetic Features of Turner Syndrome

Turner syndrome = Monosomy X - loss of one sex chromosome in phenotypic females.

Cytogenetics:

Classic: 45,X (monosomy X) - most common (50-60%)
Mosaicism: 45,X/46,XX (milder phenotype)
Isochromosome: 46,X,i(Xq) - long arm duplicated
Ring chromosome: 46,X,r(X)
Deletion: 46,X,del(Xp) - short arm deletion

Mechanism: Non-disjunction (meiosis I or II) or anaphase lag. Paternal sex chromosome lost in 70-80% of cases.

Clinical Features:

At birth/infancy:

Lymphedema of hands and feet (puffiness)
Loose skin at nape of neck (pterygium colli / webbed neck)
Low birth weight

Classic triad:

Short stature (most consistent feature; <150 cm)
Webbed neck (pterygium colli)
Primary amenorrhea / gonadal dysgenesis (streak ovaries → infertility)

Other features:

Shield-shaped chest with widely spaced nipples
Cubitus valgus (increased carrying angle)
Low posterior hairline
High-arched palate
Bicuspid aortic valve (most common cardiac defect), coarctation of aorta
Horseshoe kidney (most common renal anomaly)
Hearing loss (conductive/sensorineural)
Normal intelligence (may have visuospatial deficits)
Hypothyroidism (autoimmune)

PART II

Q.4 - Classify Shock, Types, Mechanism and Stages (2+3+5 = 10)

Classification of Shock (2 marks)

Shock = Generalized failure of adequate perfusion of tissues, leading to cellular hypoxia and organ dysfunction.

Class	Types
Hypovolemic	Hemorrhagic, non-hemorrhagic (burns, dehydration)
Cardiogenic	MI, cardiomyopathy, arrhythmias, cardiac tamponade
Distributive	Septic, anaphylactic, neurogenic
Obstructive	Pulmonary embolism, tension pneumothorax, cardiac tamponade

Types with Examples (3 marks)

Hypovolemic shock - Loss of circulating volume. Example: trauma with hemorrhage, severe burns, cholera (fluid loss). Pathology: ↓ preload → ↓ CO → ↓ BP → tissue hypoperfusion.
Cardiogenic shock - Heart fails as a pump. Example: massive MI (>40% LV loss), fulminant myocarditis. Pathology: ↓ CO despite normal or ↑ filling pressures → pulmonary edema + hypoperfusion.
Septic shock (commonest distributive) - Overwhelming infection. Example: gram-negative sepsis (E.coli, Klebsiella). Endotoxin (LPS) → TNF-α, IL-1, IL-6 → vasodilation, ↑ vascular permeability → ↓ SVR, maldistribution of flow. Mixed picture: initially hyperdynamic (warm shock); later hypodynamic (cold shock).
Anaphylactic shock - IgE-mediated hypersensitivity. Example: penicillin reaction, bee sting. Massive histamine/complement release → vasodilation + bronchospasm.
Neurogenic shock - Loss of vasomotor tone due to spinal cord injury. Loss of sympathetic outflow → vasodilation, bradycardia.

Mechanism and Stages of Shock (5 marks)

General Mechanism: Any cause → ↓ tissue perfusion → cells switch to anaerobic metabolism → lactic acidosis → cellular swelling, membrane pump failure → cell death → organ failure → death.

Stages:

Stage 1 - Compensated (Non-progressive) Shock:

Baroreceptors sense ↓ BP → SNS activation
Compensatory responses:
- Tachycardia (↑HR to maintain CO)
- Vasoconstriction (↑SVR via epinephrine, angiotensin II, vasopressin)
- RAAS activation → sodium + water retention
- Skin: cool, pale, clammy (blood diverted to vital organs)
- Oliguria (ADH + aldosterone)
BP maintained near normal; reversible

Stage 2 - Progressive (Decompensated) Shock:

Compensatory mechanisms overwhelmed
Hypotension becomes evident
Widespread tissue hypoxia → anaerobic glycolysis → ↑lactate → metabolic acidosis
Acidosis impairs cardiac function further
Vasoactive mediators (NO, histamine, bradykinin) → vasodilation despite SNS
Endothelial injury → microvascular thrombosis (DIC) begins
Ischemia of gut → bacterial translocation → endotoxemia (perpetuates shock)
Still potentially reversible with vigorous treatment

Stage 3 - Irreversible Shock:

Severe, prolonged hypoperfusion → cellular death
Multi-organ dysfunction syndrome (MODS):
- Acute tubular necrosis (kidneys)
- Acute Respiratory Distress Syndrome - ARDS (lungs)
- Centrilobular necrosis (liver)
- Stress ulcers (GIT)
- DIC (hematological)
- Brain: irreversible neurological damage
Reperfusion injury (free radicals) worsens damage
Death inevitable despite treatment

Q.5 - Describe Briefly (5 marks each)

a. Peripheral Smear Findings in Megaloblastic Anemia

Megaloblastic anemia is caused by impaired DNA synthesis (Vitamin B12 or folate deficiency) → nuclear maturation lags behind cytoplasmic maturation.

Red Cell Findings:

Macrocytes - MCV >100 fL
Macro-ovalocytes (Macro-ovalocytosis) - large, oval red cells; most characteristic
Anisocytosis and poikilocytosis
Tear-drop cells (dacryocytes)
Hypersegmented nucleated RBCs occasionally

White Cell Findings:

Hypersegmented neutrophils - ≥5 lobes in >5% neutrophils, OR any neutrophil with ≥6 lobes - MOST PATHOGNOMONIC FINDING
Neutropenia in severe cases

Platelet Findings:

Thrombocytopenia (severe cases)
Large (giant) platelets

Bone Marrow (for completeness):

Hypercellular
Megaloblasts: large cells with fine, open (sieve-like) chromatin, cytoplasm mature (hemoglobinized) but nucleus immature - "nuclear-cytoplasmic dissociation"
Giant metamyelocytes and band forms
Hypersegmented megakaryocytes

Note: Peripheral smear often shows pancytopenia (anemia + leukopenia + thrombocytopenia) due to ineffective hematopoiesis.

b. Differences Between AML and ALL

Feature	AML (Acute Myeloid Leukemia)	ALL (Acute Lymphoblastic Leukemia)
Age	Adults (median 65 yrs); ↑ with age	Children (peak 2-5 yrs); most common childhood cancer
Cell of origin	Myeloid progenitor	Lymphoid progenitor (B or T cell)
Morphology (FAB)	M0-M7 (8 subtypes); Auer rods (pathognomonic)	L1, L2, L3 (3 types); No Auer rods
Auer Rods	Present (myeloperoxidase +)	Absent
Special stain	MPO +, Sudan Black B +, NSE + (M5/M4)	PAS + (blocks), MPO -, TdT +
Immunophenotype	CD13, CD33, CD117, CD34	B-ALL: CD19, CD10, TdT; T-ALL: CD3, CD7
Cytogenetics	t(8;21) - M2 (good prognosis); t(15;17) - M3 APL; inv(16) - M4; FLT3 mutation	t(12;21) - B-ALL (good); t(9;22) - Ph+ ALL (poor); t(8;14) - L3/Burkitt
CNS involvement	Less common	Common (CNS prophylaxis given)
Prognosis	Overall worse; APL (M3) excellent with ATRA	Children: 90% CR; Adults: worse
Treatment	"3+7" (cytarabine + anthracycline); ATRA for APL	Induction: vincristine, prednisolone, asparaginase
DIC	M3 (APL) - classic association	Rare
Gum hypertrophy	M4/M5 (monocytic)	Absent

c. Laboratory Diagnosis of Haemophilia A

Haemophilia A = Factor VIII deficiency (X-linked recessive)

Screening Tests:

Test	Result
aPTT (activated partial thromboplastin time)	PROLONGED - most important screening test; tests intrinsic pathway
Prothrombin Time (PT)	Normal (extrinsic pathway intact)
Bleeding Time (BT)	Normal (platelet function intact)
Platelet Count	Normal
Thrombin Time (TT)	Normal

Confirmatory Tests:

Factor VIII assay - Reduced Factor VIII activity (<1% = severe; 1-5% = moderate; 5-40% = mild)
Factor IX assay - Normal (differentiates from Haemophilia B which has ↓Factor IX)
Bethesda assay - Detects Factor VIII inhibitors (antibodies) - done before treatment

Mixing Study:

Patient plasma + normal plasma (1:1) → aPTT corrects in simple deficiency; does NOT correct if inhibitor present

Genetic/Molecular:

Inversion mutation at intron 22 of F8 gene (accounts for 45-50% of severe cases)
Useful for carrier detection and prenatal diagnosis

d. Hodgkin's Lymphoma vs Non-Hodgkin's Lymphoma

Feature	Hodgkin's Lymphoma	Non-Hodgkin's Lymphoma
Age	Bimodal: 15-35 yrs & >50 yrs	Any age; increases with age
Pathognomonic cell	Reed-Sternberg (RS) cell - large binucleate/"owl-eye" nucleoli; CD15+, CD30+	No RS cells; malignant lymphocytes
Node involvement	Contiguous spread (predictable)	Non-contiguous (skip lesions)
Mediastinal involvement	Common (especially NS type)	Less common
Extranodal involvement	Rare	Common (Waldeyer's ring, GIT, CNS)
B symptoms	Present	May be present
Splenic involvement	Miliary nodules	Diffuse involvement
Bone marrow	Rare (except advanced)	Common
Classification	WHO 2022: Classical (NS, MC, LR, LD) + NLPHL	B-cell (DLBCL, Follicular, Burkitt) and T-cell types
Staging	Ann Arbor (I-IV) - sufficient	Ann Arbor; also IPI score for prognosis
Treatment	ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)	Depends on type: CHOP-R for DLBCL
Prognosis	Generally better (5-yr survival >80% for early stages)	Variable; some very aggressive (Burkitt's)
EBV association	Mixed cellularity type	Burkitt's lymphoma

e. Infections Transmitted Through Blood Transfusion

Viral:

HIV (most feared; window period transmission possible)
Hepatitis B (HBsAg + anti-HBc tested; window period ~50 days)
Hepatitis C (RNA testing reduces window period to ~7 days)
Hepatitis A (rare; no carrier state)
CMV (Cytomegalovirus) - risk to immunocompromised and neonates; use CMV-negative or leukodepleted blood
HTLV-I/II (T-cell lymphoma/leukemia, tropical spastic paraparesis)
Parvovirus B19 - aplastic crisis in hemolytic anemias
West Nile Virus, Dengue - emerging concerns
EBV

Bacterial (most common cause of fatality in transfusion):

Gram-negative organisms (grow at 4°C in RBC) - Yersinia enterocolitica, Pseudomonas
Gram-positive - Staphylococcus (platelet contamination - stored at RT)
Treponema pallidum (syphilis) - killed by refrigeration; rarely transmitted now

Parasitic:

Malaria (Plasmodium - all species; most common in tropical countries including India)
Chagas disease (Trypanosoma cruzi) - Latin America
Leishmaniasis (Leishmania)
Babesiosis (Babesia) - US

Prions:

Variant Creutzfeldt-Jakob disease (vCJD) - UK donors with BSE exposure excluded

Prevention in India: NBTC mandates screening for HIV, HBsAg, HCV, Malaria, and Syphilis for all donated blood.

Q.6 - Describe Very Briefly (2 marks each)

a. Clinical Consequences of Obesity

(BMI >30 kg/m²)

System	Consequence
Metabolic	Type 2 Diabetes Mellitus (insulin resistance), Dyslipidemia (↑TG, ↓HDL)
Cardiovascular	Hypertension, Coronary artery disease, LVH, Congestive heart failure, Stroke
Respiratory	Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome (Pickwickian)
GIT	NAFLD/NASH → cirrhosis, GERD, Gallstones (↑cholesterol)
Endocrine	Polycystic ovarian syndrome (PCOS), Infertility, Early puberty
Musculoskeletal	Osteoarthritis (knees, hips), Gout
Cancer	Endometrial, breast, colon, esophageal, renal cancers
Skin	Acanthosis nigricans, Intertrigo, Striae
Psychological	Depression, poor self-esteem

b. Local and Systemic Factors Influencing Wound Healing

Local Factors:

Infection - delays healing (bacterial toxins, enzymes destroy matrix)
Blood supply - poor vascularization impairs delivery of oxygen/nutrients
Foreign body / necrotic tissue - impedes healing
Type and extent of injury - large wounds heal slower; incised heals better than crushed
Movement - excessive movement disrupts granulation tissue
Radiation - damages endothelial cells and fibroblasts
Edema / hematoma - separates wound edges; nidus for infection

Systemic Factors:

Nutrition - Protein deficiency (impairs collagen synthesis), Vitamin C deficiency (poor collagen cross-linking), Zinc deficiency (impairs metalloenzymes)
Diabetes mellitus - vascular disease, neuropathy, impaired neutrophil function, ↑infection
Corticosteroids - inhibit collagen synthesis, suppress inflammation
Old age - reduced regenerative capacity
Anemia / hypoxia - impairs oxidative killing and collagen synthesis
Immunodeficiency - HIV, chemotherapy → infection susceptibility
Drugs - NSAIDs, anticoagulants
Jaundice / uremia - impair healing

c. Pathogenesis of Primary Amyloidosis

Primary (AL) amyloidosis is caused by plasma cell dyscrasia (monoclonal plasma cells in bone marrow, associated with multiple myeloma or MGUS).

Steps:

Monoclonal plasma cell proliferation (usually lambda light chains) in bone marrow
Plasma cells secrete excess immunoglobulin light chains (Bence Jones proteins) - free lambda (or kappa) light chains
These light chains or their fragments misfold into beta-pleated sheet configuration (the pathological conformation)
Misfolded proteins aggregate extracellularly as amyloid fibrils (7.5-10 nm diameter, non-branching, rigid)
Amyloid fibrils deposit in organs - kidneys, heart, liver, spleen, nerves, tongue, skin
Amyloid associated proteins accumulate: SAP (serum amyloid P), Apolipoprotein E, HSPG (heparan sulfate proteoglycan)
Deposition compresses and destroys parenchyma → organ dysfunction

Staining: Congo Red stain → apple-green birefringence under polarized light (pathognomonic)

Organs affected: Kidney (nephrotic syndrome), Heart (restrictive cardiomyopathy), Liver (hepatomegaly), Peripheral nerves (neuropathy), Tongue (macroglossia - characteristic of AL)

d. Differences Between Transudate and Exudate

Feature	Transudate	Exudate
Mechanism	Hydrostatic pressure ↑ OR oncotic pressure ↓	Inflammation → ↑ vascular permeability
Protein content	Low (<3 g/dL)	High (>3 g/dL)
Specific gravity	Low (<1.012)	High (>1.020)
LDH	Low (<200 IU/L)	High (>200 IU/L)
Cells	Few, mainly mesothelial	Many (neutrophils in acute; lymphocytes in chronic)
Clotting	Does NOT clot	May clot (fibrinogen present)
Glucose	Same as serum	Low (consumed by cells/bacteria)
Appearance	Clear, straw-colored	Cloudy, may be purulent or hemorrhagic
Causes	CCF, nephrotic syndrome, liver cirrhosis, hypoalbuminemia	Infection, malignancy, TB, rheumatoid arthritis, pancreatitis
Light's criteria	Does NOT meet any Light's criteria	Meets ≥1 of: protein ratio >0.5, LDH ratio >0.6, LDH >2/3 upper normal

e. Modes of Spread of Malignant Tumours with Examples

1. Direct / Local Spread (Invasion):

Tumor cells infiltrate adjacent tissues by secreting proteases (MMPs) and losing E-cadherin adhesion
Example: Carcinoma cervix invading bladder/rectum; Glioblastoma invading brain parenchyma

2. Lymphatic Spread (most common for carcinomas):

Tumor emboli travel via lymphatics to regional nodes → "sentinel node" → further nodes
Initially to regional nodes; later systemic
Example: Breast carcinoma → axillary nodes; Carcinoma stomach → left supraclavicular node (Virchow's node / Troisier's sign); Prostatic cancer → iliac nodes

3. Hematogenous Spread (most common for sarcomas):

Tumor cells enter veins (thin-walled; arteries more resistant)
Liver (portal drainage), Lungs (systemic veins), Bone (vertebral venous plexus - Batson's plexus)
Examples:
- Hepatocellular carcinoma → lungs and bone
- Follicular thyroid carcinoma → lungs and bone
- Renal cell carcinoma → lungs ("cannonball" metastases)
- Prostate → bone (osteoblastic)

4. Transcoelomic / Seeding in body cavities:

Tumor cells shed into peritoneal, pleural, or pericardial cavities
Example: Carcinoma ovary → peritoneal deposits (causing ascites); Carcinoma stomach → bilateral ovarian deposits (Krukenberg tumor); Mesothelioma

5. Perineural Spread:

Along nerve sheaths
Example: Carcinoma prostate, adenoid cystic carcinoma (parotid)

6. Cerebrospinal fluid (CSF) spread:

Medulloblastoma, ependymoma → "drop metastases" along spinal cord

Note on Q5f (medical student skills question): This is a non-pathology question asking about professional development. The expected answer touches on clinical skills (history, examination), communication, teamwork, empathy, evidence-based practice, ethical conduct, and patient safety. For a pathology exam, this seems out of scope - you can write ~3-4 sentences if needed.

Good luck with your exam! These answers follow standard Robbins Pathology and Harrison's level expected for 2nd year MBBS. For diagrams, draw the granuloma structure for Q3a, CML phases table for Q2d, and the shock flowchart for Q4 - examiners reward diagrams.

This is a shared conversation. Sign in to Orris to start your own chat.